Tumour necrosis factor antagonists: structure, function, and tuberculosis risks

被引：191
|
作者：
Walls, Robert S. [1 ]
机构：
[1] Pfizer Global Res & Dev, New London, CT 06320 USA
来源：
LANCET INFECTIOUS DISEASES | 2008年 / 8卷 / 10期
关键词：
D O I：
10.1016/S1473-3099(08)70227-5
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Our understanding of the infection risks presented by tumour necrosis factor (TNF) antagonists has continued to evolve in the 10 years since these drugs were first introduced. Several recent studies have confirmed the increased risk of tuberculosis posed by TNF antibodies compared with soluble TNF receptor, particularly with regard to reactivation of latent infection. Structural and functional differences seem to account for this finding. This Review examines the potential relations between target specificity, stoichiometry, and binding kinetics of TNF blockers and their associated risk of infection. Clinical strategies for prevention and management of tuberculosis in patients treated with TNF blockers may be improved based on our evolving understanding of these differences.
引用
收藏
页码：601 / 611
页数：11
相关论文
共 50 条
  • [41] Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis
    Van Doornum, S
    McColl, G
    Wicks, IP
    RHEUMATOLOGY, 2005, 44 (11) : 1428 - 1432
  • [42] Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: Effectiveness comparative study
    Arenere Mendoza, Mercedes
    Manero Ruiz, Francisco Javier
    Carrera Lasfuentes, Patricia
    Navarro Aznarez, Herminia
    Pecondon Espanol, Angela
    Rabanaque Hernandez, Maria Jose
    MEDICINA CLINICA, 2010, 134 (15): : 665 - 670
  • [43] Treatment with tumour necrosis factor a antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies
    Jonsdottir, T
    Forslid, J
    van Vollenhoven, A
    Harju, A
    Brannemark, S
    Klareskog, L
    van Vollenhoven, RF
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (09) : 1075 - 1078
  • [44] Tumour necrosis factor antagonists selectively downregulate the Th17 response in psoriasis
    Prinz, J.
    Vollmer, S.
    Nickel, J.
    Besgen, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) : E20 - E20
  • [45] Efficacy and Safety of Tumour Necrosis Factor Antagonists in a Large Cohort of Juvenile Dermatomyositis Patients
    Campanilho-Marques, Raquel
    Deakin, Claire
    Simou, Stephanie
    Wedderburn, Lucy R.
    Pilkington, Clarissa
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [46] Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists?
    Victoria Hernandez, Maria
    Ruiz-Esquide, Virginia
    Eugenia Gomez-Caballero, Maria
    Gomez-Puerta, Jose A.
    Canete, Juan D.
    Sanmarti, Raimon
    RHEUMATOLOGY, 2011, 50 (08) : 1523 - 1525
  • [47] Active Tuberculosis Incidence In Patients Treated With Tumor Necrosis Factor Antagonists According To Latent Tuberculosis Infection
    Lee, E.
    Park, J.
    Mo, L. Jung
    Lee, S.
    Kang, Y.
    Jung, J.
    Suk, P. Moo
    Ahn, C.
    Kim, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [48] Immunosuppressants/tumour necrosis factor antagonistsInflammation and pulmonary tuberculosis: 2 case reports
    Reactions Weekly, 2007, 1159 (1) : 18 - 18
  • [49] Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: An Asian perspective
    To, Kin Wang
    Gomez Reino, Juan J.
    Yoo, Dae Hyun
    Tam, Lai Shan
    RESPIROLOGY, 2013, 18 (05) : 765 - 773
  • [50] Tumour necrosis factor inhibitors/antitubercularsActive tuberculosis and hepatotoxicity: 7 case reports
    Reactions Weekly, 2015, 1544 (1) : 228 - 228
12345